ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Company management will present at two investor conferences in the coming weeks. The live webcast of each presentation can be accessed through the “Investor Information” section of the Company’s website, www.immunogen.com; a replay of each presentation will be available at the same location for one week.

  • NewsMakers in the Biotech Industry Conference
    9:00 a.m. ET on October 22, 2010 in New York, NY
    Presenter: Daniel Junius, President and CEO
  • Oppenheimer 21st Annual Healthcare Conference
    1:00 p.m. ET on November 3, 2010 in New York, NY
    Presenter: Gregory Perry, Senior Vice President and CFO

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGen’s collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at www.immunogen.com.



CONTACT:

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
[email protected]
or
For Media:
The Yates Network
Adriana Jenkins, 617-744-1713

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Suggested Articles

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.